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Abstract 
Background: Cell‑free RNA (cfRNA) transcripts known to be expressed by the fetal brain are detectable by quantita‑
tive reverse transcription PCR (RT‑qPCR) in amniotic fluid and represent potential biomarkers of neurodevelopment. 
The aim of this study was to compare the cfRNA yields from amniotic fluid (AF) collected in a commercial RNA stabili‑
zation product with the traditional method of freezing alone.
Findings: Thirteen women undergoing elective Cesarean birth at term without labor had whole AF collected at the 
time of uterine incision, prior to membrane rupture. Patient samples were split between Streck RNA blood collection 
tubes (BCT) and plain sterile polypropylene centrifuge tubes. Cell‑free RNA from the AF supernatant was extracted 
according to a previously published protocol. RT qPCR was performed for the reference gene GAPDH, and three genes 
associated with neurodevelopment (NRXN3, NTRK3, and ZBTB18). The yield from samples collected in Streck RNA BCT 
and plain centrifuge tubes were compared with the paired t test. GAPDH, NRXN3 and ZBTB18 amplified successfully 
in all samples, but NTRK3 did not. The RNA yield was significantly lower in samples collected in the Streck RNA BCT 
compared with the traditional storage method of freezing alone for all three successfully amplified genes (p < 0.0001).
Conclusions: Selected cfRNA neurodevelopment transcripts are consistently detectable in third trimester AF. There 
appears to be no benefit in collecting AF in Streck RNA BCT for quantitative studies of AF cell‑free RNA.
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Findings
Introduction
For most couples facing a diagnosis of a fetal abnormal-
ity, the projected neurodevelopmental outcome for their 
baby is of primary importance. To date, our methods of 
antenatal prediction of long term neurodevelopmental 
outcome has been confined to only a few modalities—
imaging with ultrasound and MRI, and maternal blood 
analysis for markers of aneuploidy or neural tube defects. 
A prenatal predictor of neurodevelopmental outcome 
that is not dependent on the presence of structural 
brain malformations would be of great value in perinatal 
medicine.
A novel approach would be to examine the genetic 
transcripts found in the amniotic fluid that encode genes 
responsible for neurodevelopment. Amniotic fluid (AF) 
cell-free RNA (cfRNA) has previously been shown to be 
a novel source of information about multiple organ sys-
tems including the fetal brain [1–3]. The majority of the 
gene expression studies on AF utilizing cfRNA have been 
performed with whole genome microarrays, with fewer 
data from RT-qPCR, which has a greater dynamic range. 
CfRNA transcripts that are (1) highly expressed by fetal 
brain, (2) detectable in AF and (3) exhibit brain-specific 
expression patterns, represent candidate biomarkers 
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of neurodevelopment that could be measured using 
RT-PCR.
Functional analysis of cfRNA suggests that is more 
promising than amniocyte RNA as a source of poten-
tial biomarkers of fetal neurodevelopment [3]. However, 
there are technical challenges involved with working with 
cfRNA, as it can be more degraded that cellular RNA. 
A prior study has demonstrated that prolonged storage 
of AF at −80  °C leads to fragmentation of the cell-free 
nucleic acids [4]. This limits the feasibility of large scale 
multicentre studies and long term biobanking for AF 
cfRNA studies.
Commercial RNA stabilization reagents have been 
developed for use with whole blood (e.g. PAXgene™ 
blood tubes, Qiagen) and saliva (RNAprotect Saliva™, 
Qiagen), but not yet for AF. A collection tube for the sta-
bilization of cfRNA in blood (Streck RNA BCT™) is also 
available. This cfRNA stabilization tube is compatible 
with the Qiagen Circulating Nucleic Acid kit used for AF 
RNA extraction, according to the manufacturer.
The aims of this study were (1) to determine if candi-
date neurodevelopmental transcripts are consistently 
detectable in AF using RT-qPCR and (2) to compare 
RNA yields from AF collected in commercial RNA sta-
bilization products with the standard method of freezing 
alone. The Mercy Health Human Research Ethics Com-
mittee approved this study (Ref. #14/20).
Methods
Consenting participants undergoing undergoing elec-
tive Cesarean section without labour were prospectively 
recruited and had whole AF collected at the time of uter-
ine incision prior to membrane rupture, as previously 
described [5]. AF samples with visible blood or meco-
nium staining were not included. Amniotic fluid samples 
were collected intraoperatively and split between Streck 
RNA BCT and the sterile centrifuge tubes. The aliquots 
processed according to the standard protocol were cen-
trifuged twice (10 min at 300×g and 10 min 1600×g) and 
the supernatant frozen at −80 °C. The whole AF aliquots 
collected in Streck RNA BCT were kept at room temper-
ature for up to 7 days (as per manufacturer’s instructions) 
before being centrifuged as above and the supernatant 
processed for cell-free RNA extraction in the same batch 
as the paired standard sample.
RNA was extracted with the Qiagen Circulating 
Nucleic Acid kit according to the previously published 
method [5]. The volume of AF supernatant for each 
extraction was 5  ml. The RNA was eluted with 100  μl 
elution buffer and in-solution DNase digestion was per-
formed as per the manufacturer’s instructions. RNA 
purification and concentration was then performed with 
the RNeasy MinElute Clean up and Concentration kit 
(Qiagen) and the final elution was performed with 16 μl 
of RNase-free water and stored at −80 °C.
Real-time quantitative PCR (qPCR) was performed 
after reverse transcription using Applied Biosystems 
High Capacity cDNA Reverse Transcription Kit accord-
ing to the manufacturer’s instructions. Quantitative gene 
expression analyses were performed with inventoried 
Taqman Gene Expression Assays (Applied Biosystems, 
Carlsbad, CA, USA) for the reference gene glyceralde-
hyde 3-phosphate dehydrogenase (GAPDH), and three 
genes associated with neurodevelopment: (1) neurexin 
3(NRXN3), a neuronal cell surface protein-encoding 
gene involved in cell recognition and adhesion; (2) neu-
rotrophic tyrosine kinase receptor type 3 (NTRK3), cell-
surface receptor involved in neurotrophin signaling of 
cell differentiation; (3) and zinc finger and BTB domain 
containing 18 (ZBTB18, alias ZNF238), a transcrip-
tional repressor of genes involved in neurodevelopment. 
These genes were selected on the basis of prior detection 
in microarray studies of AF [2, 6], documented tissue 
expression in human fetal brain [7] and fetal brain spe-
cific expression (defined as expression  >10 multiples of 
the median in a publicly-available gene expression atlas 
[8]). The qPCR reactions were performed in duplicate 
on the CFX 384 (BioRad, Foster City, CA, USA), with 
the following cycling conditions: 50  °C for 2 min, 95  °C 
for 10 min, and 40 cycles of 95 °C for 15 s, and 60 °C for 
1 min.
Results
Thirteen women consented to participate and had suc-
cessful amniotic fluid collection at the time of Cesarean 
section. All AF samples were processed within 7  days. 
The reference gene GAPDH successfully amplified in all 
samples. Of the candidate neurodevelopmental genes, 
ZBTB18 and NRXN3 amplified in all samples. However, 
NTRK3 was present in very low abundance and failed to 
amplify in 50 % of total aliquots, precluding any statisti-
cal analysis.
For each of the genes, paired t-tests were performed 
between the mean cycle threshold (Ct) to determine if 
there was a statistically significant difference in expres-
sion according to collection method. The mean Ct results 
did not demonstrate any improvement in RNA yield with 
Streck RNA BCT compared with the conventional collec-
tion and storage method. In fact, the RNA collected and 
stored with the conventional method resulted in amplifi-
cation of all genes at a significantly lower Ct (i.e. higher 
abundance), with the mean Ct difference of −3.12, −2.39 
and −2.47 for GAPDH, NRXN and ZBTB18 respectively 
(p < 0.0001 for all three genes) (Fig. 1).
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Discussion
This study confirmed that cell-free transcripts NRXN3 
and ZBTB18 are consistently detectable in term amniotic 
fluid supernatant. There appears to be no benefit in col-
lecting whole AF in Streck RNA BCT over plain centri-
fuge tubes for studies of AF cell-free RNA.
One of the major challenges of working with cell-free 
RNA is assessing the quality of the extracted product. 
Conventional methods of assessing RNA quality such as 
the RNA Integrity Number (RIN) produced by the Agi-
lent 2100 Bioanalyzer system uses ribosomal RNA peaks 
to quantify the quality of RNA. Cell-free RNA does not 
contain these ribosomal RNA peaks and therefore does 
not produce a meaningful RIN. In prior work, we found 
that quantification of GAPDH using RT-qPCR corre-
lated well with downstream amplification and microarray 
hybridization success [9]. In this study, the GAPDH yield 
was lower with the Streck samples compared with the 
standard methods, indicating no benefit to using Streck 
BCT for whole AF sample collection.
This lack of improvement with the use of an RNA sta-
bilizing product may be due to the already degraded 
nature of AF cfRNA at the time of sampling, and implies 
that there is minimum room for optimization of AF RNA 
yield with stabilization reagents. Furthermore, the Streck 
RNA BCT is designed for stabilizing cfRNA in whole 
blood, and it is not optimized for AF, which may contain 
additional substances that interfere with its performance.
The failure to consistently detect NTRK3 in all sam-
ples is consistent with prior whole transcriptome analysis 
demonstrating that neurological system gene expression 
is relatively downregulated in term samples compared 
with midgestation [5, 10].
Another potential reason for the low yield was the 
omission of carrier RNA from the RNA extraction step 
[10]. This was omitted in the original protocol due to its 
potential interference in downstream steps such as whole 
transcriptome amplification. However, it may be suitable 
to include in future experiments where these considera-
tions are not applicable.
In summary, this study has confirmed the presence of 
several potential mRNA markers of neurodevelopment 
with RT qPCR. Further research is required to optimize 
sample collection and storage for future studies of AF 
cfRNA.
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Fig. 1 Paired mean Ct values for GAPDH, NRXN3 and ZBTB18 in amniotic fluid samples stored in Streck RNA BCT at room temperature vs plain centri‑
fuge tubes frozen at −80 °C (p < 0.0001 for all three genes)
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